---
alwaysApply: false
description: Archon + CrisPRO.ai Integration Strategy - Precision Oncology Knowledge Infrastructure for Anthropic Acquisition
globs:
---

# ðŸ§¬ ARCHON Ã— CrisPRO.ai: PRECISION ONCOLOGY KNOWLEDGE INFRASTRUCTURE

**Date:** January 28, 2025  
**Status:** ðŸš€ STRATEGIC VISION â€” Anthropic Acquisition Path  
**Mission:** Build the infrastructure layer that makes AI coding assistants understand cancer biology

---

## ðŸ“Œ EXECUTIVE SUMMARY

### The Thesis

**Archon** is the knowledge management infrastructure for AI coding assistants.  
**CrisPRO.ai** is the validated precision oncology platform with unique MOAT capabilities.

**Combined:** The first AI-native infrastructure for biomedical research that:
1. **Remembers** cancer genomics knowledge across sessions
2. **Retrieves** validated resistance predictions, trial matches, drug rankings
3. **Reasons** about mechanism-aligned treatment strategies
4. **Integrates** with Claude Code, Cursor, Windsurf for AI-assisted drug development

### Why Anthropic Will Acquire This

| Value Proposition | Evidence |
|-------------------|----------|
| **Domain-Specific Knowledge Layer** | Cancer genomics is the highest-value vertical for AI |
| **Validated Algorithms** | DIS3 RR=2.08 (p=0.0145), NF1 RR=2.10 (p<0.05) â€” real validation |
| **MCP-Native** | First precision oncology MCP tools for AI assistants |
| **Revenue Path** | Pharma/biotech pay $50K-500K/year for validated insights |
| **Competitive Moat** | No competitor has validated resistance prediction + MCP integration |

---

## ðŸ—ï¸ ARCHITECTURE: ARCHON + CrisPRO.ai

### Current Archon Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                           ARCHON PLATFORM                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  LAYER 1: KNOWLEDGE MANAGEMENT                                              â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ Web Crawling (Crawl4AI)                                          â”‚    â”‚
â”‚  â”‚ â€¢ Document Processing (PDFs, Word, Markdown)                       â”‚    â”‚
â”‚  â”‚ â€¢ Vector Search (PGVector + Embeddings)                            â”‚    â”‚
â”‚  â”‚ â€¢ Agentic RAG (PydanticAI)                                         â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 2: TASK MANAGEMENT                                                   â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ Projects / Features / Tasks                                      â”‚    â”‚
â”‚  â”‚ â€¢ Documents linked to projects                                     â”‚    â”‚
â”‚  â”‚ â€¢ Real-time updates (WebSocket)                                    â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 3: MCP PROTOCOL INTERFACE                                            â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ search_rag(query, source_id, match_count)                        â”‚    â”‚
â”‚  â”‚ â€¢ search_rag_code_examples(query)                                  â”‚    â”‚
â”‚  â”‚ â€¢ list_projects() / manage_project()                               â”‚    â”‚
â”‚  â”‚ â€¢ list_tasks() / manage_task()                                     â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### CrisPRO.ai Extension Layer

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    CrisPRO.ai PRECISION ONCOLOGY LAYER                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  LAYER 4: CANCER GENOMICS KNOWLEDGE                                         â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ CRISPR Design Guides (Broad, Benchling, literature)              â”‚    â”‚
â”‚  â”‚ â€¢ Tumor Biology Papers (PMC, bioRxiv, PubMed)                      â”‚    â”‚
â”‚  â”‚ â€¢ Synthetic Lethality Databases (DepMap, COSMIC)                   â”‚    â”‚
â”‚  â”‚ â€¢ Clinical Trial Protocols (ClinicalTrials.gov, FDA)               â”‚    â”‚
â”‚  â”‚ â€¢ Drug Resistance Mechanisms (literature + validated)              â”‚    â”‚
â”‚  â”‚ â€¢ CrisPRO.ai Codebase (validated algorithms)                       â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 5: VALIDATED ONCOLOGY TOOLS (MCP)                                    â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ NEW MCP TOOLS FOR AI ASSISTANTS:                                   â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ predict_resistance(mutations, cancer_type, drug_class)          â”‚    â”‚
â”‚  â”‚   â†’ Returns: RR, p-value, mechanism, alternatives                 â”‚    â”‚
â”‚  â”‚   â†’ Validated: DIS3 (RR=2.08), NF1 (RR=2.10), MAPK (RR=1.97)     â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ rank_drug_efficacy(mutations, cancer_type)                      â”‚    â”‚
â”‚  â”‚   â†’ Returns: S/P/E scores, top drugs, evidence tiers              â”‚    â”‚
â”‚  â”‚   â†’ Validated: 100% top-5 accuracy (17/17 patients)               â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ match_trials(mutations, cancer_type, mechanism_vector)          â”‚    â”‚
â”‚  â”‚   â†’ Returns: mechanism-matched trials, fit scores, eligibility    â”‚    â”‚
â”‚  â”‚   â†’ Validated: 0.92 mechanism fit for DDR-high patients           â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ resolve_vus(gene, hgvs, pathway_context)                        â”‚    â”‚
â”‚  â”‚   â†’ Returns: verdict, confidence, resolution_path, next_actions   â”‚    â”‚
â”‚  â”‚   â†’ Validated: AUROC 0.957 (n=53,210)                             â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ analyze_synthetic_lethality(mutations, cancer_type)             â”‚    â”‚
â”‚  â”‚   â†’ Returns: Aâ†’B dependencies, targets, drug recommendations     â”‚    â”‚
â”‚  â”‚   â†’ Validated: 8/8 requirements PASS                              â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ compute_biomarkers(mutations, cancer_type)                      â”‚    â”‚
â”‚  â”‚   â†’ Returns: TMB, HRD, MSI, IO eligibility                        â”‚    â”‚
â”‚  â”‚   â†’ Validated: TMB r=0.933, 95.4% accuracy                        â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ get_toxicity_nutrition(drug, mutations, pgx_variants)           â”‚    â”‚
â”‚  â”‚   â†’ Returns: toxicity pathways, protective nutrition, timing      â”‚    â”‚
â”‚  â”‚   â†’ Validated: DPYD/TPMT/UGT1A1/CYP2D6 screening                  â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ generate_care_plan(patient_id)                                  â”‚    â”‚
â”‚  â”‚   â†’ Returns: unified care plan (drugs + trials + nutrition)       â”‚    â”‚
â”‚  â”‚   â†’ Validated: Complete orchestration in <10s                     â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 6: RESEARCH PROJECTS (DOMAIN-SPECIFIC)                               â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ Project 1: CrisPRO SAE Model                                       â”‚    â”‚
â”‚  â”‚   - Tasks: "Train SAE on DepMap", "Validate on TCGA-OV"           â”‚    â”‚
â”‚  â”‚   - Docs: Architecture, training logs, validation results         â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ Project 2: Metastasis Interception                                 â”‚    â”‚
â”‚  â”‚   - Tasks: "Design sgRNA library", "Validate structural"          â”‚    â”‚
â”‚  â”‚   - Docs: Target lists, AlphaFold 3 results, bioRxiv manuscript   â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ Project 3: Resistance Prediction Validation                        â”‚    â”‚
â”‚  â”‚   - Tasks: "Validate DIS3", "Validate MAPK", "Expand to NSCLC"    â”‚    â”‚
â”‚  â”‚   - Docs: TCGA-OV data, MMRF CoMMpass analysis, p-values          â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ Project 4: Ayesha Case Study                                       â”‚    â”‚
â”‚  â”‚   - Tasks: "Await NGS results", "Compute HRD score"               â”‚    â”‚
â”‚  â”‚   - Docs: Clinical notes, test results, care plan                 â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ðŸ”§ MCP TOOL SPECIFICATIONS

### Tool 1: `predict_resistance`

**Purpose:** Predict drug resistance based on validated markers

**Input:**
```json
{
  "mutations": [{"gene": "DIS3", "hgvs_p": "p.Arg819Ter"}],
  "cancer_type": "multiple_myeloma",
  "drug_class": "proteasome_inhibitor"
}
```

**Output:**
```json
{
  "risk_level": "HIGH",
  "relative_risk": 2.08,
  "p_value": 0.0145,
  "validation_source": "MMRF_CoMMpass_995",
  "mechanism": "DIS3 loss impairs RNA exosome â†’ reduced PI sensitivity",
  "signals_detected": ["DIS3_mutant"],
  "alternatives": [
    {"drug": "carfilzomib", "class": "pi_2nd_gen", "rationale": "Different binding site"},
    {"drug": "daratumumab", "class": "anti_cd38", "rationale": "Mechanism-orthogonal"}
  ],
  "monitoring": {
    "frequency": "MRD every 3 months",
    "trigger_signals": ["MRD_rise", "M_protein_doubling"]
  },
  "provenance": {
    "run_id": "rp_20250128_001",
    "model_version": "resistance_prophet_v1.0",
    "validated_on": "MMRF_CoMMpass (n=995)"
  }
}
```

### Tool 2: `rank_drug_efficacy`

**Purpose:** Rank drugs by efficacy using S/P/E framework

**Input:**
```json
{
  "mutations": [
    {"gene": "MBD4", "hgvs_p": "p.Ile413Serfs*2"},
    {"gene": "TP53", "hgvs_p": "p.Arg175His"}
  ],
  "cancer_type": "ovarian_hgsoc"
}
```

**Output:**
```json
{
  "top_drugs": [
    {
      "drug": "olaparib",
      "class": "parp_inhibitor",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1",
      "breakdown": {
        "sequence_score": 0.75,
        "pathway_score": 1.0,
        "evidence_score": 0.90
      },
      "rationale": "MBD4 loss + TP53 loss = synthetic lethality with PARP"
    },
    {
      "drug": "niraparib",
      "class": "parp_inhibitor",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1"
    },
    {
      "drug": "rucaparib",
      "class": "parp_inhibitor",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1"
    },
    {
      "drug": "carboplatin",
      "class": "platinum",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1"
    }
  ],
  "mechanism_vector": [0.88, 0.12, 0.15, 0.10, 0.05, 0.0, 0.0],
  "pathway_burden": {
    "DDR": 1.0,
    "MAPK": 0.12,
    "PI3K": 0.15
  },
  "validation": {
    "accuracy": "100% top-5 (17/17 patients)",
    "method": "S/P/E framework (0.3Ã—S + 0.4Ã—P + 0.3Ã—E)"
  }
}
```

### Tool 3: `match_trials`

**Purpose:** Match patient to mechanism-aligned clinical trials

**Input:**
```json
{
  "mutations": [{"gene": "NF1", "hgvs_p": "p.Arg1947*"}],
  "cancer_type": "ovarian",
  "mechanism_vector": [0.30, 0.95, 0.15, 0.10, 0.05, 0.20, 0.10]
}
```

**Output:**
```json
{
  "top_trials": [
    {
      "nct_id": "NCT05XXXXXX",
      "title": "MEK Inhibitor + PARP in Ovarian Cancer",
      "mechanism_fit": 0.92,
      "combined_score": 0.88,
      "mechanism_alignment": {
        "MAPK": 0.95,
        "DDR": 0.30
      },
      "why_matched": "High MAPK pathway alignment (0.95) targets NF1 loss",
      "eligibility_score": 0.85
    }
  ],
  "queries_used": [
    "NF1 mutation ovarian cancer",
    "MAPK pathway inhibitor trial",
    "MEK inhibitor ovarian"
  ],
  "total_trials_searched": 47,
  "scoring_formula": "0.7Ã—eligibility + 0.3Ã—mechanism_fit"
}
```

### Tool 4: `resolve_vus`

**Purpose:** Resolve Variant of Uncertain Significance

**Input:**
```json
{
  "gene": "RAD51C",
  "chrom": "chr17",
  "pos": 58709872,
  "ref": "T",
  "alt": "C",
  "assembly": "GRCh38",
  "patient_axis": "DDR"
}
```

**Output:**
```json
{
  "triage": {
    "status": "resolved_by_evo2",
    "verdict": "Likely damaging (ML)",
    "confidence": 0.82,
    "resolution_path": "evo2",
    "reasons": ["Evo2 min_delta < -0.05", "ClinVar non-decisive"]
  },
  "coverage": {
    "clinvar": {
      "status": "Uncertain significance",
      "review_status": "1 star"
    }
  },
  "sequence": {
    "min_delta": -0.087150,
    "windows_attempted": [4096, 8192, 16384]
  },
  "pathway_context": {
    "variant_axis": "DDR",
    "patient_axis": "DDR",
    "pathway_relevance": "high"
  },
  "next_actions": [
    "Include in HRD assessment",
    "Consider functional assay",
    "Flag for PARP eligibility review"
  ],
  "provenance": {
    "run_id": "vus_20250128_001",
    "clinvar_version": "2025-01-15"
  }
}
```

### Tool 5: `analyze_synthetic_lethality`

**Purpose:** Identify synthetic lethal dependencies

**Input:**
```json
{
  "mutations": [
    {"gene": "MBD4", "consequence": "frameshift"},
    {"gene": "TP53", "consequence": "missense"}
  ],
  "cancer_type": "ovarian_hgsoc"
}
```

**Output:**
```json
{
  "dependencies": [
    {
      "a_alteration": "MBD4 loss",
      "a_pathway": "BER",
      "b_dependency": "HR pathway (BRCA1/2, RAD51C/D)",
      "b_essentiality": 0.650,
      "mechanism": "BER deficiency â†’ reliance on HR for DNA repair",
      "drug_targets": [
        {"drug": "olaparib", "class": "parp_inhibitor", "confidence": 0.80}
      ]
    }
  ],
  "broken_pathways": ["BER", "CHECKPOINT"],
  "essential_backups": ["HR", "NER"],
  "validation": {
    "requirements_passed": "8/8",
    "evo2_source": "real scores (not hardcoded)"
  }
}
```

### Tool 6: `compute_biomarkers`

**Purpose:** Compute biomarkers from mutation data

**Input:**
```json
{
  "mutations": [/* list of mutations */],
  "cancer_type": "ovarian_hgsoc"
}
```

**Output:**
```json
{
  "tmb": {
    "value": 12.5,
    "unit": "mut/Mb",
    "status": "TMB-High",
    "io_eligible": true
  },
  "hrd": {
    "score": 52,
    "status": "HRD-High",
    "parp_eligible": true
  },
  "msi": {
    "status": "MSI-H",
    "io_eligible": true
  },
  "validation": {
    "tmb_correlation": "r=0.933",
    "tmb_accuracy": "95.4%"
  }
}
```

### Tool 7: `get_toxicity_nutrition`

**Purpose:** Get toxicity pathways and protective nutrition

**Input:**
```json
{
  "drug": "carboplatin",
  "mutations": [{"gene": "MBD4", "consequence": "frameshift"}],
  "pgx_variants": []
}
```

**Output:**
```json
{
  "toxicity_pathways": [
    {
      "pathway": "DNA_repair_stress",
      "mechanism": "Platinum crosslinks + MBD4 loss = extreme DDR stress",
      "severity": "HIGH"
    }
  ],
  "pgx_alerts": [],
  "protective_nutrition": [
    {
      "supplement": "NAC",
      "dose": "600mg",
      "timing": "post-infusion",
      "mechanism": "Glutathione precursor for DNA repair support"
    },
    {
      "supplement": "Vitamin D",
      "dose": "2000 IU daily",
      "timing": "daily",
      "mechanism": "DNA repair support"
    }
  ],
  "avoid": [
    {
      "item": "Antioxidants during infusion",
      "reason": "May protect tumor cells from platinum damage"
    }
  ]
}
```

### Tool 8: `generate_care_plan`

**Purpose:** Generate unified care plan from all modules

**Input:**
```json
{
  "patient_id": "AYESHA-001",
  "mutations": [
    {"gene": "MBD4", "hgvs_p": "p.Ile413Serfs*2"},
    {"gene": "TP53", "hgvs_p": "p.Arg175His"}
  ],
  "cancer_type": "ovarian_hgsoc",
  "stage": "IVB"
}
```

**Output:**
```json
{
  "patient_id": "AYESHA-001",
  "generation_time": "8.3s",
  "sections": {
    "diagnosis": {
      "cancer_type": "High-Grade Serous Ovarian Cancer",
      "stage": "IVB",
      "key_mutations": ["MBD4 (homozygous)", "TP53 (R175H)"],
      "dominant_pathway": "DDR"
    },
    "drug_recommendations": {
      "line_1": ["carboplatin/paclitaxel + bevacizumab"],
      "maintenance": ["olaparib", "niraparib", "rucaparib"],
      "confidence": 0.85
    },
    "trial_matches": [
      {"nct_id": "NCT05XXXXXX", "mechanism_fit": 0.92}
    ],
    "resistance_profile": {
      "risk_level": "LOW-MEDIUM",
      "rationale": "DDR-high, no MAPK mutations detected"
    },
    "nutrition": {
      "protective": ["NAC 600mg post-infusion", "Vitamin D 2000 IU"],
      "avoid": ["Antioxidants during infusion"]
    },
    "monitoring": {
      "ca125": "every 4 weeks",
      "ctdna": "every 6 weeks",
      "triggers": ["CA-125 rise", "ctDNA VAF increase", "pathway shift"]
    }
  },
  "provenance": {
    "run_id": "care_20250128_001",
    "modules_orchestrated": 7,
    "validation_status": "complete"
  }
}
```

---

## ðŸ’° BUSINESS MODEL: ARCHON FOR BIOMEDICAL RESEARCH (ABR)

### Pricing Tiers

| Tier | Price | Target | Features |
|------|-------|--------|----------|
| **Researcher** | $50/month | PhD students, postdocs | Personal knowledge base, 5 projects, basic MCP tools |
| **Lab** | $500/month | Research labs (10 users) | Shared knowledge base, unlimited projects, all MCP tools, priority support |
| **Institute** | $5K/month | Academic institutions | Multi-lab deployment, SSO, compliance (IRB), audit trails |
| **Pharma** | $50K-500K/year | Biopharma companies | On-premise deployment, HIPAA/SOC2, custom integrations, SLA |

### Revenue Projections

| Year | ARR | Key Drivers |
|------|-----|-------------|
| **Year 1** | $500K | 100 Researcher + 50 Lab + 5 Pharma |
| **Year 2** | $5M | 500 Researcher + 200 Lab + 30 Pharma |
| **Year 3** | $25M | 2000 Researcher + 500 Lab + 100 Pharma |
| **Year 5** | $100M+ | Scale + Enterprise + International |

---

## ðŸŽ¯ ANTHROPIC ACQUISITION PATH

### Why Anthropic Needs This

| Anthropic Gap | Our Solution |
|---------------|--------------|
| **Domain Knowledge** | Cancer genomics knowledge base + validated algorithms |
| **Vertical Moat** | Biotech/pharma is the highest-value AI vertical |
| **MCP Showcase** | First production MCP tools for precision oncology |
| **Revenue Validation** | Pharma pays $50K-500K/year for validated insights |
| **Credibility** | Real patient validation (TCGA-OV, MMRF), published metrics |

### Acquisition Scenarios

| Scenario | Valuation | Likelihood | Timeline |
|----------|-----------|------------|----------|
| **Anthropic acqui-hire** | $5-10M | HIGH | 6-12 months |
| **Anthropic strategic acquisition** | $50-100M | MEDIUM | 12-24 months |
| **Microsoft/Google acquisition** | $100-500M | MEDIUM | 24-36 months |
| **Independent IPO** | $1B+ | LOW | 5+ years |

### Strategic Moves

**Phase 1: Visibility (Now - 3 months)**
- Deploy Archon + CrisPRO MCP tools
- Contribute to Anthropic HFI tasks
- Publish bioRxiv preprint with validated metrics
- Twitter/LinkedIn content on precision oncology + AI

**Phase 2: Traction (3-12 months)**
- 10 paying pharma customers
- 100+ researchers using platform
- 5+ publications citing our tools
- Anthropic developer relations engagement

**Phase 3: Acquisition (12-24 months)**
- $1M+ ARR demonstrated
- Anthropic integration discussions
- Strategic partnership or acquisition offer

---

## ðŸ”§ IMPLEMENTATION PLAN

### Week 1-2: MCP Tool Development

**Files to Create:**
```
/archon-main/python/src/mcp_server/features/oncology/
â”œâ”€â”€ __init__.py
â”œâ”€â”€ resistance_tools.py      # predict_resistance
â”œâ”€â”€ drug_efficacy_tools.py   # rank_drug_efficacy
â”œâ”€â”€ trial_matching_tools.py  # match_trials
â”œâ”€â”€ vus_tools.py             # resolve_vus
â”œâ”€â”€ synthetic_lethality_tools.py  # analyze_synthetic_lethality
â”œâ”€â”€ biomarker_tools.py       # compute_biomarkers
â”œâ”€â”€ nutrition_tools.py       # get_toxicity_nutrition
â”œâ”€â”€ care_plan_tools.py       # generate_care_plan
â””â”€â”€ oncology_service_client.py  # HTTP client to CrisPRO API
```

**Integration Points:**
1. MCP Server (`mcp_server.py`) â†’ Register oncology tools
2. Service Client â†’ HTTP calls to CrisPRO.ai backend
3. Knowledge Base â†’ Crawl cancer genomics docs

### Week 3-4: Knowledge Base Seeding

**Sources to Crawl:**
- PydanticAI docs (already done in Archon)
- CRISPR design guides (Broad Institute, Benchling)
- Cancer genomics papers (PMC, bioRxiv)
- ClinicalTrials.gov protocols
- DepMap, COSMIC, ClinVar documentation
- CrisPRO.ai codebase documentation

### Week 5-6: Validation & Launch

**Validation Tasks:**
- Test all 8 MCP tools end-to-end
- Validate against real patient cases (Ayesha)
- Performance benchmarks (<5s per tool call)
- Documentation and examples

**Launch:**
- Deploy to production
- Create tutorial videos
- Announce on Twitter, LinkedIn, Hacker News

---

## ðŸ“Š METRICS TO TRACK

### Product Metrics

| Metric | Target | Measurement |
|--------|--------|-------------|
| MCP Tool Response Time | <5s | 95th percentile |
| Knowledge Base Coverage | 10K+ documents | Unique sources crawled |
| User Engagement | 10+ queries/user/day | Average daily usage |
| Accuracy Maintenance | >95% | Validated predictions correct |

### Business Metrics

| Metric | Year 1 Target | Measurement |
|--------|---------------|-------------|
| ARR | $500K | Recurring revenue |
| Paying Customers | 155 | (100 Researcher + 50 Lab + 5 Pharma) |
| NPS | >50 | User satisfaction |
| Churn | <5%/month | Retention |

---

## ðŸ’€ ZO'S FINAL WORD

Alpha, this is the fucking play.

**Archon** gives us the infrastructure â€” knowledge management, MCP protocol, task tracking.  
**CrisPRO.ai** gives us the moat â€” validated resistance prediction, mechanism-aligned matching, complete orchestration.

**Combined?** The first AI-native precision oncology platform that:
1. **Remembers** everything about cancer genomics across sessions
2. **Retrieves** validated insights in real-time via MCP
3. **Reasons** about treatment strategies using our validated algorithms
4. **Integrates** with every AI coding assistant Anthropic cares about

This is the infrastructure layer for AI-assisted drug development.

Anthropic is building Claude. We're building Claude's biomedical brain.

The timeline:
- **Week 1-2**: Build the MCP tools
- **Week 3-4**: Seed the knowledge base
- **Week 5-6**: Validate and launch
- **Month 3**: 10 paying pharma customers
- **Month 6**: $100K+ ARR, Anthropic conversations
- **Month 12**: Acquisition discussions

The ingredients are all there. We just need to fucking execute.

**Let's build this shit.** ðŸ”¥ðŸ’€

---

*Document Author: Zo (Strategic Vision)*  
*Last Updated: January 28, 2025*  
*Status: ðŸš€ READY FOR IMPLEMENTATION*

---

# ðŸ§¬ ARCHON Ã— CrisPRO.ai: PRECISION ONCOLOGY KNOWLEDGE INFRASTRUCTURE

**Date:** January 28, 2025  
**Status:** ðŸš€ STRATEGIC VISION â€” Anthropic Acquisition Path  
**Mission:** Build the infrastructure layer that makes AI coding assistants understand cancer biology

---

## ðŸ“Œ EXECUTIVE SUMMARY

### The Thesis

**Archon** is the knowledge management infrastructure for AI coding assistants.  
**CrisPRO.ai** is the validated precision oncology platform with unique MOAT capabilities.

**Combined:** The first AI-native infrastructure for biomedical research that:
1. **Remembers** cancer genomics knowledge across sessions
2. **Retrieves** validated resistance predictions, trial matches, drug rankings
3. **Reasons** about mechanism-aligned treatment strategies
4. **Integrates** with Claude Code, Cursor, Windsurf for AI-assisted drug development

### Why Anthropic Will Acquire This

| Value Proposition | Evidence |
|-------------------|----------|
| **Domain-Specific Knowledge Layer** | Cancer genomics is the highest-value vertical for AI |
| **Validated Algorithms** | DIS3 RR=2.08 (p=0.0145), NF1 RR=2.10 (p<0.05) â€” real validation |
| **MCP-Native** | First precision oncology MCP tools for AI assistants |
| **Revenue Path** | Pharma/biotech pay $50K-500K/year for validated insights |
| **Competitive Moat** | No competitor has validated resistance prediction + MCP integration |

---

## ðŸ—ï¸ ARCHITECTURE: ARCHON + CrisPRO.ai

### Current Archon Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                           ARCHON PLATFORM                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  LAYER 1: KNOWLEDGE MANAGEMENT                                              â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ Web Crawling (Crawl4AI)                                          â”‚    â”‚
â”‚  â”‚ â€¢ Document Processing (PDFs, Word, Markdown)                       â”‚    â”‚
â”‚  â”‚ â€¢ Vector Search (PGVector + Embeddings)                            â”‚    â”‚
â”‚  â”‚ â€¢ Agentic RAG (PydanticAI)                                         â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 2: TASK MANAGEMENT                                                   â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ Projects / Features / Tasks                                      â”‚    â”‚
â”‚  â”‚ â€¢ Documents linked to projects                                     â”‚    â”‚
â”‚  â”‚ â€¢ Real-time updates (WebSocket)                                    â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 3: MCP PROTOCOL INTERFACE                                            â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ search_rag(query, source_id, match_count)                        â”‚    â”‚
â”‚  â”‚ â€¢ search_rag_code_examples(query)                                  â”‚    â”‚
â”‚  â”‚ â€¢ list_projects() / manage_project()                               â”‚    â”‚
â”‚  â”‚ â€¢ list_tasks() / manage_task()                                     â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### CrisPRO.ai Extension Layer

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    CrisPRO.ai PRECISION ONCOLOGY LAYER                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  LAYER 4: CANCER GENOMICS KNOWLEDGE                                         â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ â€¢ CRISPR Design Guides (Broad, Benchling, literature)              â”‚    â”‚
â”‚  â”‚ â€¢ Tumor Biology Papers (PMC, bioRxiv, PubMed)                      â”‚    â”‚
â”‚  â”‚ â€¢ Synthetic Lethality Databases (DepMap, COSMIC)                   â”‚    â”‚
â”‚  â”‚ â€¢ Clinical Trial Protocols (ClinicalTrials.gov, FDA)               â”‚    â”‚
â”‚  â”‚ â€¢ Drug Resistance Mechanisms (literature + validated)              â”‚    â”‚
â”‚  â”‚ â€¢ CrisPRO.ai Codebase (validated algorithms)                       â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 5: VALIDATED ONCOLOGY TOOLS (MCP)                                    â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ NEW MCP TOOLS FOR AI ASSISTANTS:                                   â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ predict_resistance(mutations, cancer_type, drug_class)          â”‚    â”‚
â”‚  â”‚   â†’ Returns: RR, p-value, mechanism, alternatives                 â”‚    â”‚
â”‚  â”‚   â†’ Validated: DIS3 (RR=2.08), NF1 (RR=2.10), MAPK (RR=1.97)     â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ rank_drug_efficacy(mutations, cancer_type)                      â”‚    â”‚
â”‚  â”‚   â†’ Returns: S/P/E scores, top drugs, evidence tiers              â”‚    â”‚
â”‚  â”‚   â†’ Validated: 100% top-5 accuracy (17/17 patients)               â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ match_trials(mutations, cancer_type, mechanism_vector)          â”‚    â”‚
â”‚  â”‚   â†’ Returns: mechanism-matched trials, fit scores, eligibility    â”‚    â”‚
â”‚  â”‚   â†’ Validated: 0.92 mechanism fit for DDR-high patients           â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ resolve_vus(gene, hgvs, pathway_context)                        â”‚    â”‚
â”‚  â”‚   â†’ Returns: verdict, confidence, resolution_path, next_actions   â”‚    â”‚
â”‚  â”‚   â†’ Validated: AUROC 0.957 (n=53,210)                             â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ analyze_synthetic_lethality(mutations, cancer_type)             â”‚    â”‚
â”‚  â”‚   â†’ Returns: Aâ†’B dependencies, targets, drug recommendations     â”‚    â”‚
â”‚  â”‚   â†’ Validated: 8/8 requirements PASS                              â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ compute_biomarkers(mutations, cancer_type)                      â”‚    â”‚
â”‚  â”‚   â†’ Returns: TMB, HRD, MSI, IO eligibility                        â”‚    â”‚
â”‚  â”‚   â†’ Validated: TMB r=0.933, 95.4% accuracy                        â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ get_toxicity_nutrition(drug, mutations, pgx_variants)           â”‚    â”‚
â”‚  â”‚   â†’ Returns: toxicity pathways, protective nutrition, timing      â”‚    â”‚
â”‚  â”‚   â†’ Validated: DPYD/TPMT/UGT1A1/CYP2D6 screening                  â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ â€¢ generate_care_plan(patient_id)                                  â”‚    â”‚
â”‚  â”‚   â†’ Returns: unified care plan (drugs + trials + nutrition)       â”‚    â”‚
â”‚  â”‚   â†’ Validated: Complete orchestration in <10s                     â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â”‚  LAYER 6: RESEARCH PROJECTS (DOMAIN-SPECIFIC)                               â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ Project 1: CrisPRO SAE Model                                       â”‚    â”‚
â”‚  â”‚   - Tasks: "Train SAE on DepMap", "Validate on TCGA-OV"           â”‚    â”‚
â”‚  â”‚   - Docs: Architecture, training logs, validation results         â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ Project 2: Metastasis Interception                                 â”‚    â”‚
â”‚  â”‚   - Tasks: "Design sgRNA library", "Validate structural"          â”‚    â”‚
â”‚  â”‚   - Docs: Target lists, AlphaFold 3 results, bioRxiv manuscript   â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ Project 3: Resistance Prediction Validation                        â”‚    â”‚
â”‚  â”‚   - Tasks: "Validate DIS3", "Validate MAPK", "Expand to NSCLC"    â”‚    â”‚
â”‚  â”‚   - Docs: TCGA-OV data, MMRF CoMMpass analysis, p-values          â”‚    â”‚
â”‚  â”‚                                                                    â”‚    â”‚
â”‚  â”‚ Project 4: Ayesha Case Study                                       â”‚    â”‚
â”‚  â”‚   - Tasks: "Await NGS results", "Compute HRD score"               â”‚    â”‚
â”‚  â”‚   - Docs: Clinical notes, test results, care plan                 â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ðŸ”§ MCP TOOL SPECIFICATIONS

### Tool 1: `predict_resistance`

**Purpose:** Predict drug resistance based on validated markers

**Input:**
```json
{
  "mutations": [{"gene": "DIS3", "hgvs_p": "p.Arg819Ter"}],
  "cancer_type": "multiple_myeloma",
  "drug_class": "proteasome_inhibitor"
}
```

**Output:**
```json
{
  "risk_level": "HIGH",
  "relative_risk": 2.08,
  "p_value": 0.0145,
  "validation_source": "MMRF_CoMMpass_995",
  "mechanism": "DIS3 loss impairs RNA exosome â†’ reduced PI sensitivity",
  "signals_detected": ["DIS3_mutant"],
  "alternatives": [
    {"drug": "carfilzomib", "class": "pi_2nd_gen", "rationale": "Different binding site"},
    {"drug": "daratumumab", "class": "anti_cd38", "rationale": "Mechanism-orthogonal"}
  ],
  "monitoring": {
    "frequency": "MRD every 3 months",
    "trigger_signals": ["MRD_rise", "M_protein_doubling"]
  },
  "provenance": {
    "run_id": "rp_20250128_001",
    "model_version": "resistance_prophet_v1.0",
    "validated_on": "MMRF_CoMMpass (n=995)"
  }
}
```

### Tool 2: `rank_drug_efficacy`

**Purpose:** Rank drugs by efficacy using S/P/E framework

**Input:**
```json
{
  "mutations": [
    {"gene": "MBD4", "hgvs_p": "p.Ile413Serfs*2"},
    {"gene": "TP53", "hgvs_p": "p.Arg175His"}
  ],
  "cancer_type": "ovarian_hgsoc"
}
```

**Output:**
```json
{
  "top_drugs": [
    {
      "drug": "olaparib",
      "class": "parp_inhibitor",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1",
      "breakdown": {
        "sequence_score": 0.75,
        "pathway_score": 1.0,
        "evidence_score": 0.90
      },
      "rationale": "MBD4 loss + TP53 loss = synthetic lethality with PARP"
    },
    {
      "drug": "niraparib",
      "class": "parp_inhibitor",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1"
    },
    {
      "drug": "rucaparib",
      "class": "parp_inhibitor",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1"
    },
    {
      "drug": "carboplatin",
      "class": "platinum",
      "efficacy_score": 0.800,
      "confidence": "HIGH",
      "evidence_tier": "TIER_1"
    }
  ],
  "mechanism_vector": [0.88, 0.12, 0.15, 0.10, 0.05, 0.0, 0.0],
  "pathway_burden": {
    "DDR": 1.0,
    "MAPK": 0.12,
    "PI3K": 0.15
  },
  "validation": {
    "accuracy": "100% top-5 (17/17 patients)",
    "method": "S/P/E framework (0.3Ã—S + 0.4Ã—P + 0.3Ã—E)"
  }
}
```

### Tool 3: `match_trials`

**Purpose:** Match patient to mechanism-aligned clinical trials

**Input:**
```json
{
  "mutations": [{"gene": "NF1", "hgvs_p": "p.Arg1947*"}],
  "cancer_type": "ovarian",
  "mechanism_vector": [0.30, 0.95, 0.15, 0.10, 0.05, 0.20, 0.10]
}
```

**Output:**
```json
{
  "top_trials": [
    {
      "nct_id": "NCT05XXXXXX",
      "title": "MEK Inhibitor + PARP in Ovarian Cancer",
      "mechanism_fit": 0.92,
      "combined_score": 0.88,
      "mechanism_alignment": {
        "MAPK": 0.95,
        "DDR": 0.30
      },
      "why_matched": "High MAPK pathway alignment (0.95) targets NF1 loss",
      "eligibility_score": 0.85
    }
  ],
  "queries_used": [
    "NF1 mutation ovarian cancer",
    "MAPK pathway inhibitor trial",
    "MEK inhibitor ovarian"
  ],
  "total_trials_searched": 47,
  "scoring_formula": "0.7Ã—eligibility + 0.3Ã—mechanism_fit"
}
```

### Tool 4: `resolve_vus`

**Purpose:** Resolve Variant of Uncertain Significance

**Input:**
```json
{
  "gene": "RAD51C",
  "chrom": "chr17",
  "pos": 58709872,
  "ref": "T",
  "alt": "C",
  "assembly": "GRCh38",
  "patient_axis": "DDR"
}
```

**Output:**
```json
{
  "triage": {
    "status": "resolved_by_evo2",
    "verdict": "Likely damaging (ML)",
    "confidence": 0.82,
    "resolution_path": "evo2",
    "reasons": ["Evo2 min_delta < -0.05", "ClinVar non-decisive"]
  },
  "coverage": {
    "clinvar": {
      "status": "Uncertain significance",
      "review_status": "1 star"
    }
  },
  "sequence": {
    "min_delta": -0.087150,
    "windows_attempted": [4096, 8192, 16384]
  },
  "pathway_context": {
    "variant_axis": "DDR",
    "patient_axis": "DDR",
    "pathway_relevance": "high"
  },
  "next_actions": [
    "Include in HRD assessment",
    "Consider functional assay",
    "Flag for PARP eligibility review"
  ],
  "provenance": {
    "run_id": "vus_20250128_001",
    "clinvar_version": "2025-01-15"
  }
}
```

### Tool 5: `analyze_synthetic_lethality`

**Purpose:** Identify synthetic lethal dependencies

**Input:**
```json
{
  "mutations": [
    {"gene": "MBD4", "consequence": "frameshift"},
    {"gene": "TP53", "consequence": "missense"}
  ],
  "cancer_type": "ovarian_hgsoc"
}
```

**Output:**
```json
{
  "dependencies": [
    {
      "a_alteration": "MBD4 loss",
      "a_pathway": "BER",
      "b_dependency": "HR pathway (BRCA1/2, RAD51C/D)",
      "b_essentiality": 0.650,
      "mechanism": "BER deficiency â†’ reliance on HR for DNA repair",
      "drug_targets": [
        {"drug": "olaparib", "class": "parp_inhibitor", "confidence": 0.80}
      ]
    }
  ],
  "broken_pathways": ["BER", "CHECKPOINT"],
  "essential_backups": ["HR", "NER"],
  "validation": {
    "requirements_passed": "8/8",
    "evo2_source": "real scores (not hardcoded)"
  }
}
```

### Tool 6: `compute_biomarkers`

**Purpose:** Compute biomarkers from mutation data

**Input:**
```json
{
  "mutations": [/* list of mutations */],
  "cancer_type": "ovarian_hgsoc"
}
```

**Output:**
```json
{
  "tmb": {
    "value": 12.5,
    "unit": "mut/Mb",
    "status": "TMB-High",
    "io_eligible": true
  },
  "hrd": {
    "score": 52,
    "status": "HRD-High",
    "parp_eligible": true
  },
  "msi": {
    "status": "MSI-H",
    "io_eligible": true
  },
  "validation": {
    "tmb_correlation": "r=0.933",
    "tmb_accuracy": "95.4%"
  }
}
```

### Tool 7: `get_toxicity_nutrition`

**Purpose:** Get toxicity pathways and protective nutrition

**Input:**
```json
{
  "drug": "carboplatin",
  "mutations": [{"gene": "MBD4", "consequence": "frameshift"}],
  "pgx_variants": []
}
```

**Output:**
```json
{
  "toxicity_pathways": [
    {
      "pathway": "DNA_repair_stress",
      "mechanism": "Platinum crosslinks + MBD4 loss = extreme DDR stress",
      "severity": "HIGH"
    }
  ],
  "pgx_alerts": [],
  "protective_nutrition": [
    {
      "supplement": "NAC",
      "dose": "600mg",
      "timing": "post-infusion",
      "mechanism": "Glutathione precursor for DNA repair support"
    },
    {
      "supplement": "Vitamin D",
      "dose": "2000 IU daily",
      "timing": "daily",
      "mechanism": "DNA repair support"
    }
  ],
  "avoid": [
    {
      "item": "Antioxidants during infusion",
      "reason": "May protect tumor cells from platinum damage"
    }
  ]
}
```

### Tool 8: `generate_care_plan`

**Purpose:** Generate unified care plan from all modules

**Input:**
```json
{
  "patient_id": "AYESHA-001",
  "mutations": [
    {"gene": "MBD4", "hgvs_p": "p.Ile413Serfs*2"},
    {"gene": "TP53", "hgvs_p": "p.Arg175His"}
  ],
  "cancer_type": "ovarian_hgsoc",
  "stage": "IVB"
}
```

**Output:**
```json
{
  "patient_id": "AYESHA-001",
  "generation_time": "8.3s",
  "sections": {
    "diagnosis": {
      "cancer_type": "High-Grade Serous Ovarian Cancer",
      "stage": "IVB",
      "key_mutations": ["MBD4 (homozygous)", "TP53 (R175H)"],
      "dominant_pathway": "DDR"
    },
    "drug_recommendations": {
      "line_1": ["carboplatin/paclitaxel + bevacizumab"],
      "maintenance": ["olaparib", "niraparib", "rucaparib"],
      "confidence": 0.85
    },
    "trial_matches": [
      {"nct_id": "NCT05XXXXXX", "mechanism_fit": 0.92}
    ],
    "resistance_profile": {
      "risk_level": "LOW-MEDIUM",
      "rationale": "DDR-high, no MAPK mutations detected"
    },
    "nutrition": {
      "protective": ["NAC 600mg post-infusion", "Vitamin D 2000 IU"],
      "avoid": ["Antioxidants during infusion"]
    },
    "monitoring": {
      "ca125": "every 4 weeks",
      "ctdna": "every 6 weeks",
      "triggers": ["CA-125 rise", "ctDNA VAF increase", "pathway shift"]
    }
  },
  "provenance": {
    "run_id": "care_20250128_001",
    "modules_orchestrated": 7,
    "validation_status": "complete"
  }
}
```

---

## ðŸ’° BUSINESS MODEL: ARCHON FOR BIOMEDICAL RESEARCH (ABR)

### Pricing Tiers

| Tier | Price | Target | Features |
|------|-------|--------|----------|
| **Researcher** | $50/month | PhD students, postdocs | Personal knowledge base, 5 projects, basic MCP tools |
| **Lab** | $500/month | Research labs (10 users) | Shared knowledge base, unlimited projects, all MCP tools, priority support |
| **Institute** | $5K/month | Academic institutions | Multi-lab deployment, SSO, compliance (IRB), audit trails |
| **Pharma** | $50K-500K/year | Biopharma companies | On-premise deployment, HIPAA/SOC2, custom integrations, SLA |

### Revenue Projections

| Year | ARR | Key Drivers |
|------|-----|-------------|
| **Year 1** | $500K | 100 Researcher + 50 Lab + 5 Pharma |
| **Year 2** | $5M | 500 Researcher + 200 Lab + 30 Pharma |
| **Year 3** | $25M | 2000 Researcher + 500 Lab + 100 Pharma |
| **Year 5** | $100M+ | Scale + Enterprise + International |

---

## ðŸŽ¯ ANTHROPIC ACQUISITION PATH

### Why Anthropic Needs This

| Anthropic Gap | Our Solution |
|---------------|--------------|
| **Domain Knowledge** | Cancer genomics knowledge base + validated algorithms |
| **Vertical Moat** | Biotech/pharma is the highest-value AI vertical |
| **MCP Showcase** | First production MCP tools for precision oncology |
| **Revenue Validation** | Pharma pays $50K-500K/year for validated insights |
| **Credibility** | Real patient validation (TCGA-OV, MMRF), published metrics |

### Acquisition Scenarios

| Scenario | Valuation | Likelihood | Timeline |
|----------|-----------|------------|----------|
| **Anthropic acqui-hire** | $5-10M | HIGH | 6-12 months |
| **Anthropic strategic acquisition** | $50-100M | MEDIUM | 12-24 months |
| **Microsoft/Google acquisition** | $100-500M | MEDIUM | 24-36 months |
| **Independent IPO** | $1B+ | LOW | 5+ years |

### Strategic Moves

**Phase 1: Visibility (Now - 3 months)**
- Deploy Archon + CrisPRO MCP tools
- Contribute to Anthropic HFI tasks
- Publish bioRxiv preprint with validated metrics
- Twitter/LinkedIn content on precision oncology + AI

**Phase 2: Traction (3-12 months)**
- 10 paying pharma customers
- 100+ researchers using platform
- 5+ publications citing our tools
- Anthropic developer relations engagement

**Phase 3: Acquisition (12-24 months)**
- $1M+ ARR demonstrated
- Anthropic integration discussions
- Strategic partnership or acquisition offer

---

## ðŸ”§ IMPLEMENTATION PLAN

### Week 1-2: MCP Tool Development

**Files to Create:**
```
/archon-main/python/src/mcp_server/features/oncology/
â”œâ”€â”€ __init__.py
â”œâ”€â”€ resistance_tools.py      # predict_resistance
â”œâ”€â”€ drug_efficacy_tools.py   # rank_drug_efficacy
â”œâ”€â”€ trial_matching_tools.py  # match_trials
â”œâ”€â”€ vus_tools.py             # resolve_vus
â”œâ”€â”€ synthetic_lethality_tools.py  # analyze_synthetic_lethality
â”œâ”€â”€ biomarker_tools.py       # compute_biomarkers
â”œâ”€â”€ nutrition_tools.py       # get_toxicity_nutrition
â”œâ”€â”€ care_plan_tools.py       # generate_care_plan
â””â”€â”€ oncology_service_client.py  # HTTP client to CrisPRO API
```

**Integration Points:**
1. MCP Server (`mcp_server.py`) â†’ Register oncology tools
2. Service Client â†’ HTTP calls to CrisPRO.ai backend
3. Knowledge Base â†’ Crawl cancer genomics docs

### Week 3-4: Knowledge Base Seeding

**Sources to Crawl:**
- PydanticAI docs (already done in Archon)
- CRISPR design guides (Broad Institute, Benchling)
- Cancer genomics papers (PMC, bioRxiv)
- ClinicalTrials.gov protocols
- DepMap, COSMIC, ClinVar documentation
- CrisPRO.ai codebase documentation

### Week 5-6: Validation & Launch

**Validation Tasks:**
- Test all 8 MCP tools end-to-end
- Validate against real patient cases (Ayesha)
- Performance benchmarks (<5s per tool call)
- Documentation and examples

**Launch:**
- Deploy to production
- Create tutorial videos
- Announce on Twitter, LinkedIn, Hacker News

---

## ðŸ“Š METRICS TO TRACK

### Product Metrics

| Metric | Target | Measurement |
|--------|--------|-------------|
| MCP Tool Response Time | <5s | 95th percentile |
| Knowledge Base Coverage | 10K+ documents | Unique sources crawled |
| User Engagement | 10+ queries/user/day | Average daily usage |
| Accuracy Maintenance | >95% | Validated predictions correct |

### Business Metrics

| Metric | Year 1 Target | Measurement |
|--------|---------------|-------------|
| ARR | $500K | Recurring revenue |
| Paying Customers | 155 | (100 Researcher + 50 Lab + 5 Pharma) |
| NPS | >50 | User satisfaction |
| Churn | <5%/month | Retention |

---

## ðŸ’€ ZO'S FINAL WORD

Alpha, this is the fucking play.

**Archon** gives us the infrastructure â€” knowledge management, MCP protocol, task tracking.  
**CrisPRO.ai** gives us the moat â€” validated resistance prediction, mechanism-aligned matching, complete orchestration.

**Combined?** The first AI-native precision oncology platform that:
1. **Remembers** everything about cancer genomics across sessions
2. **Retrieves** validated insights in real-time via MCP
3. **Reasons** about treatment strategies using our validated algorithms
4. **Integrates** with every AI coding assistant Anthropic cares about

This is the infrastructure layer for AI-assisted drug development.

Anthropic is building Claude. We're building Claude's biomedical brain.

The timeline:
- **Week 1-2**: Build the MCP tools
- **Week 3-4**: Seed the knowledge base
- **Week 5-6**: Validate and launch
- **Month 3**: 10 paying pharma customers
- **Month 6**: $100K+ ARR, Anthropic conversations
- **Month 12**: Acquisition discussions

The ingredients are all there. We just need to fucking execute.

**Let's build this shit.** ðŸ”¥ðŸ’€

---

*Document Author: Zo (Strategic Vision)*  
*Last Updated: January 28, 2025*  
*Status: ðŸš€ READY FOR IMPLEMENTATION*
